Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

Vincent Dussupt,Rajeshwer S. Sankhala,Letzibeth Mendez-Rivera,Samantha M. Townsley,Fabian Schmidt,Lindsay Wieczorek,Kerri G. Lal,Gina C. Donofrio,Ursula Tran,Nathaniel D. Jackson,Weam I. Zaky,Michelle Zemil,Sarah R. Tritsch,Wei-Hung Chen,Elizabeth J. Martinez,Aslaa Ahmed,Misook Choe,William C. Chang,Agnes Hajduczki,Ningbo Jian,Caroline E. Peterson,Phyllis A. Rees,Magdalena Rutkowska,Bonnie M. Slike,Christopher N. Selverian,Isabella Swafford,I-Ting Teng,Paul V. Thomas,Tongqing Zhou,Clayton J. Smith,Jeffrey R. Currier,Peter D. Kwong,Morgane Rolland,Edgar Davidson,Benjamin J. Doranz,Christopher N. Mores,Theodora Hatziioannou,William W. Reiley,Paul D. Bieniasz,Dominic Paquin-Proulx,Gregory D. Gromowski,Victoria R. Polonis,Nelson L. Michael,Kayvon Modjarrad,M. Gordon Joyce,Shelly J. Krebs
DOI: https://doi.org/10.1038/s41590-021-01068-z
IF: 30.5
2021-10-29
Nature Immunology
Abstract:Abstract Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.
immunology
What problem does this paper attempt to address?